我的購物車 (0)
我的帳號資料
我的訂單紀錄
我的學校教授
我的學校課程

[ Tips ] 一分鐘使用導覽

搜尋 
請輸入欲查詢之關鍵字
 
  進階搜尋
依主題瀏覽 
依商品類型瀏覽 
依出版日期瀏覽 
依作者瀏覽(姓) 
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
V
W
Y
Z
銷售排行榜 
 您所選取的商品項目

> Guangzhou Kingmed Diagnostics: Post-IPO Transformation

商品編號: W25196
出版日期: 2021/10/17
作者姓名:
Hwarng, H. Brian;Yuan, Xuchuan
商品類別: Other
商品規格: 17p

再版日期:
地域: China
產業: Healthcare sector;Healthcare service industry
個案年度: -  

 


商品敘述:

Guangzhou KingMed Diagnostics was the leading third-party independent clinical laboratory in China. On the eve of the Lunar New Year in 2020, the chairman and CEO of Guangzhou KingMed Diagnostics mobilized the whole group to respond to the outbreak of the new coronavirus from Wuhan. With the group''s tremendous growth in both business and size since its initial public offering, there were growing concerns about the provision of quality customer service and the group''s profitability. While the chairman and CEO was proud to see how swiftly his team had responded to the COVID-19 pandemic, he had many questions about the efficiency of the entire group''s resource deployment and the consistency of performance across subsidiaries. Post COVID-19, how should Guangzhou KingMed Diagnostics adjust its transformation strategy? H. Brian Hwarng is affiliated with National University of Singapore.


涵蓋領域:

Operations strategy;Production


相關資料:

Case Teaching Note, (W25197), 15p, by H. Brian Hwarng, Xuchuan Yuan